Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Curcumin, Lupeol and Piperine Inhibit the Bacterial Triggers of some Autoimmune Inflammatory Diseases and Potentiate the Activity of Conventional Antibiotics

    Web AdminBy Web AdminApril 10, 2022Updated:April 12, 2022No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Audric Puisais1, Ian E Cock1,2,*
    1School of Environment and Science, Griffith University, Nathan, Queensland, AUSTRALIA.
    2Centre for Planetary Health and Food Security, Nathan Campus, Griffith University, Nathan, Queensland, AUSTRALIA.
    DOI: 10.5530/pc.2022.2.14

    ABSTRACT

    Background: Curcumin, lupeol and piperine are phytochemical constituents of multiple plants that are used traditionally to treat inflammation, including for treating autoimmune inflammatory diseases. Despite this, relatively few studies have examined the ability of these compounds to inhibit the etiological events of these diseases by examining their ability to inhibit their bacterial triggers. Methods: The ability of curcumin, lupeol and piperine to inhibit the growth of some bacterial triggers of selected autoimmune inflammatory diseases was screened using disc diffusion assays and quantified by liquid dilution MIC assays. The ΣFIC of the pure plant compound/conventional antibiotic combinations was determined and used to classify the class of interaction. Toxicity was evaluated using the Artemia nauplii cytotoxicity assay. Results: Curcumin, lupeol and piperine strongly inhibited the growth of several bacterial triggers of autoimmune diseases, with MIC values as low as 178 μg/mL against some bacteria. Furthermore, combining these compounds with conventional antibiotics resulted in significant potentiation of the inhibitory activity for some combinations, with one synergistic and nineteen additive combinations detected. Notably, three antagonistic combinations were also noted. None of the individual components (nor the combinations) were significantly toxic in the ALA toxicity assay. Conclusion: Curcumin, lupeol and piperine inhibit the growth of some bacterial triggers of rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis and rheumatic fever. Additionally, these compounds substantially potentiated the effects of some conventional antibiotics against these bacteria. Further in vivo studies to determine the anti-inflammatory and antibacterial mechanisms are warranted.

    Key words: Curcumin, Lupeol, Piperine, Antibacterial activity, Synergy, Rheumatoid arthritis, Ankylosing spondylitis, Multiple sclerosis.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up